Reinhard von Roemeling
Technik-/Wissenschafts-/F&E-Leiter bei CURIS, INC.
Aktive Positionen von Reinhard von Roemeling
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CURIS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 13.08.2019 | - |
Karriereverlauf von Reinhard von Roemeling
Ehemalige bekannte Positionen von Reinhard von Roemeling
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Reinhard von Roemeling
Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Deutschland | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CURIS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Reinhard von Roemeling
- Erfahrung